Harshman, Lauren C <br/><br/>
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.  [electronic resource] 

 -  American journal of clinical oncology  Oct 2008 
 - 417-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1537-453X 
<br/><br/><label>Standard No.: </label>10.1097/COC.0b013e318168ef47  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bone Neoplasms--drug therapy<br/>Capecitabine<br/>Carcinoma, Renal Cell--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Liver Neoplasms--drug therapy<br/>Lung Neoplasms--drug therapy<br/>Lymphatic Metastasis<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Nephrectomy<br/>Survival Rate<br/>Thalidomide--administration & dosage<br/>Treatment Outcome